Novartis, Adamis keep swinging at EpiPen with Symjepi pediatric dose

28th September 2018 Uncategorised 0

Novartis’ Sandoz is getting ready to stir things up in the epinephrine market—and as of Thursday, it has a green light to stir things up in the pediatric epinephrine market, too.

More: Novartis, Adamis keep swinging at EpiPen with Symjepi pediatric dose
Source: fierce